Protox received approval to use a new factory for the development of botulinum toxin (Botox). Through this, the process of preparing for toxin approval began in earnest.

Protox, a bio venture company, announced on the 8th that it received construction permission for a botulinum toxin manufacturing plant located in Hyangnam Pharmaceutical Complex, Hwaseong-si, Gyeonggi-do as of the 4th. The completion ceremony is scheduled to be held around the end of April. Protox is a subsidiary of DSK.

The new factory has a single-scale production capacity of 2.7 million vials. It was designed according to the latest GMP standards and met the Ministry of Food and Drug Safety approval conditions. In addition, it is explained that every effort has been made to improve safety and efficiency by establishing the entire production process as an automated system.

Protox said, “We plan to export botulinum toxin products produced at this factory starting in 2020, and are currently applying for patents and conducting research and development with the goal of domestic approval and launch at the end of 2022.”

He added, “We are continuously conducting research and development with the goal of developing high-purity, next-generation products with improved toxin formulation and performance.”

[Money Today Broadcasting MTN = Reporter Lee Dae-ho (robin@mtn.co.kr)]